Such accelerated T1D development in CMC-treated mice was observed in mice housed in different cages and was accompanied by a precocious increase in serum insulin autoantibody level evident by 4 weeks following the beginning of the treatment (Fig. 1c), with such seropositivity being an early event in T1D development1. The gene discussed is INS; the disease is type 1 diabetes mellitus.